European drug regulatory bodies and GlaxoSmithKline have quickly rallied their rebuttals to a BMJ report that questioned the safety profile of GSK’s now-unavailable pandemic flu vaccine Pandemrix...
It isn’t a scene one would expect after the world battled a severe flu season. But in China, supply of flu vaccines this season has come down, thanks to reduced offering from Sanofi Pasteur..
Seqirus has big plans for its cell-based flu vaccine franchise, and after a scale-up to reach 20 million doses this year, the company still needs more capacity.